Forest, TransTech sign licensing deal for diabetes drug

06/8/2010 | Wall Street Journal, The · Bloomberg Businessweek

Forest Laboratories signed a license agreement with TransTech Pharma to develop and commercialize glucose-lowering agents for diabetes. The deal, worth as much as $1.11 billion, will give Forest exclusive rights to the resulting treatment in international markets except the Middle East and North Africa, where TransTech will keep its license.

View Full Article in:

Wall Street Journal, The · Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC